

February 26, 2016



# **Actinium Pharmaceuticals to Present at the 28th Annual ROTH Conference**

**Company Presentation Scheduled for Tuesday, March 15, 2016 at 4:00 pm PT**

NEW YORK, NY -- (Marketwired) -- 02/26/16 --

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium"), is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today that members of its executive management team will attend the 28<sup>th</sup> Annual ROTH Conference being held March 13 - 16, 2016 at the Ritz Carlton, Orange County in Laguna Niguel, California. Sandesh Seth, Actinium's Executive Chairman, will present an overview of the Company on Tuesday, March 15, 2016 at 4:00 PM PT.

Management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting please contact Steve O'Loughlin, Senior Director, Finance and Corporate Development at [soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com).

## ***About Actinium Pharmaceuticals***

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate lomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of lomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

## ***Forward-Looking Statement for Actinium Pharmaceuticals, Inc.***

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial

performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT:

Steve O'Loughlin

Senior Director, Finance and Corporate Development

Actinium Pharmaceuticals, Inc.

[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

Source: Actinium Pharmaceuticals